Star Source Multitrade Limited Announces Website Domain Transition

Star Source Multitrade Limited , formerly known as Chemo Pharma Laboratories Limited, has officially announced a change in its website domain as part of its corporate rebranding initiative. The company communicated this development to the Bombay Stock Exchange on January 05, 2025, ensuring compliance with regulatory disclosure requirements.

Domain Transition Details

The company has transitioned from its previous website domain thechemopharmalaboratoriesltd.com to its new corporate domain starsourcemultitrade.com. This change reflects the company's rebranding from Chemo Pharma Laboratories Limited to Star Source Multitrade Limited.

Parameter:	Details
Old Domain:	thechemopharmalaboratoriesltd.com
New Domain:	starsourcemultitrade.com
Transition Date:	January 05, 2025
Script ID:	506365
ISIN:	INE320M01019

Technical Implementation

The company has implemented a comprehensive transition strategy to ensure uninterrupted access for users. All information from the old website will be permanently redirected to the new domain, maintaining continuity of content and services. This technical approach ensures that existing users can seamlessly access the same resources previously available on the former domain.

Regulatory Compliance

The domain change notification has been made in compliance with Regulation 46 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has taken necessary steps to ensure the transition meets all regulatory requirements for listed entities.

Corporate Information

The notification was signed by Ruchit Mehta, Managing Director and Chief Executive Officer (DIN: 08810586), on behalf of Star Source Multitrade Limited. The company operates under CIN: L46900MH1942PLC003556 and maintains its listing on the Bombay Stock Exchange with Script ID 506365.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
0.0%	-100.00%	-100.00%	-100.00%	-100.00%	-100.00%

Star Source Multi Trade Limited (formerly Chemo Pharma Laboratories Ltd) has received regulatory approval from BSE Limited for the reclassification of promoters from the promoter group category to public shareholders. The company announced on December 12, 2025, that it has received no-objection letters from BSE for the reclassification under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

BSE Approval Details

The BSE granted its no-objection through letter number LIST/COMP/SJ/610/2025-26 dated December 12, 2025, for the reclassification request originally submitted on September 10, 2025. This approval follows the company's previous announcements dated August 11, 2025, and December 03, 2025, regarding the receipt of request letters from outgoing promoter group shareholders.

Promoters Being Reclassified

The reclassification involves two entities moving from promoter group to public shareholder category:

Entity:	Status
Shanta Somani:	Individual Promoter
Citric India Limited:	Promoter Group Entity

Additional Regulatory Disclosure

On December 26, 2025, the company filed additional details for its earlier corporate announcement dated April 16, 2025, regarding key management resignations. The company acknowledged that it had inadvertently not mentioned required details under SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, in its original announcement.

April 2025 Resignations Details

The additional disclosure covers three key resignations that occurred on April 16, 2025:

Position:	Name	Reason for Resignation
Executive Director & CEO:	Mr. Bhavin Sheth	Other commitments and pre-occupations
Executive Director & CFO:	Shri. Ashok Somani	Other commitments and pre-occupations
Company Secretary:	Mrs. Unnatti Jain (ACS39639)	Other commitments and pre-occupations

Previous Corporate Changes

The company has undergone significant transformation following its Annual General Meeting held on September 24, 2025. Key changes included:

Leadership Appointments

Ruchit Mehta appointed as Managing Director & CEO with 4.50 years of consultancy and management experience
Utsav Trivedi designated as Executive Director & CFO with 2.00 years in accounting and financial management
Three Independent Directors joined: Sarvagya Goel (Company Secretary since 2016), Shilpy Chopra (Company Secretary with B.Com), and Simran Tripathi (Graduate and Inter Chartered Accountant)

Auditor Changes

M/s. Arvind Sudra & Associates appointed as Secretarial Auditors for 2025-2030
M/s. SSRV & Associates (Chartered Accountants) designated as Statutory Auditors for the same period

Name Change Completion

Shareholders had previously approved changing the company name from "Chemo Pharma Laboratories Limited" to "STARSOURCE MULTITRADE LIMITED", along with alterations to the Object Clause of the Memorandum of Association. All AGM resolutions were passed with 99.997% votes in favor.

Regulatory Compliance

The company is required to ensure compliance with subsequent relevant disclosures of material events related to this reclassification in accordance with applicable provisions of Regulation 31A of SEBI (LODR) Regulations, 2015. The latest filing demonstrates the company's commitment to maintaining proper regulatory compliance and transparency in its corporate disclosures.

These developments complete a significant transition period for the company, marking the final regulatory approval for its promoter structure changes alongside its rebranding and leadership transformation.